Purpose: To analyze the clinical and pathological characteristics, treatment, and prognosis of high-grade B-cell lymphomas, not otherwise specified (HGBL, NOS), and to increase awareness of this type of lymphoma. Patients and Methods: We collected clinical and pathological data of 41 cases of newly diagnosed HGBL, NOS, and analyzed diagnosis, prognosis and treatment to examine progression-free survival (PFS) and overall survival (OS). Results: Among the 41 cases studied, the median PFS was 6.0 months and the median OS was 18.0 months. Compared with patients treated with the R-CHOP regimen, patients treated with a high-intensity chemotherapy (DA-EPOCH-R, R-CODOX-M/IVAC, or R-Hyper-CVAD) had superior PFS and OS (PFS: χ .156, P=0.001). Conclusion: HGBL, NOS is associated with a high degree of malignancy, short survival period, and substantial extranodal involvement. High-intensity chemotherapy may improve patient prognosis. While IPI scores statistically correlated with the prognosis, SHL and DEL correlated with an inferior survival rate. New and improved treatments will be needed for HGBL, NOS.
Introduction
High-grade B-cell lymphoma (HGBL) is a newly introduced category in the updated 2016 revision of the World Health Organization (WHO) classification, which primarily replaces "B-cell lymphoma, unclassifiable, with features intermediate between a diffuse large B cell lymphoma (DLBCL) and the Burkitt lymphoma (BL) (BCLU, DLBCL/BL)." Currently, HGBL comprises 2 types of lymphomas: HGBL with MYC and BCL2 and/or BCL6 rearrangements (HGBL, R) and highgrade B-cell lymphomas, not otherwise specified (HGBL, NOS). [1] [2] [3] [4] [5] HGBL, R is also called a double/triple-hit lymphoma (HGBL, DH/TH). 6 HGBL, NOS do not contain MYC and BCL2 or BCL6 gene rearrangements, but present morphologies between DLBCL and BL. HGBL, NOS belong to a type of gray zone lymphomas, as they are rarely encountered in the clinic, and their etiology and pathogenesis remain unclear.
better study of the pathological and clinical features of the tumors. While a standard treatment has not been established for HGBL, NOS, 8 the following regimens have been used at the National Comprehensive Cancer Network member institutions: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine), DA-EPOCH-R (rituximab, dose-adjusted doxorubicin, cyclophosphamide, vincristine, etoposide, prednisone), R-Hyper-CVAD (rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine), R-CODOX-M/IVAC (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate alternating with ifosfamide, etoposide, and cytarabine), in consolidation with a high-dose therapy with an autologous hematopoietic stem cell transplantation (ASCT). Although the pathological features and clinical characteristics of patients with HGBL, DH/TH have been well characterized in the literature, 5, 6 few studies have focused on patients with HGBL, NOS. We retrospectively analyzed a group of patients with HGBL, NOS and summarized the clinical and the pathological features, and explored the patient diagnosis, treatment, and prognosis. We hope to improve the medical community's understanding of this type of tumor.
Methods

Clinical Characteristics
We collected data from 1802 patients with a newly diagnosed aggressive mature B-cell lymphomas, from 
Statistical Analysis
All data were analyzed using the SPSS 24.0. The survival rates (PFS and OS) of each group were estimated using the Kaplan-Meier method, and the survival rates were compared between two groups by a Log rank test. All P values <0.05 were considered statistically significant.
Results
Morphological, Immunophenotypic, and Cytogenetic Features
The included 41 patient samples presented medium-sized cell characteristics, with thin, scattered nuclei or the BLlike nuclei, some with a "starry sky" phenomenon. These morphological changes were uncertain but overall, cell sizes and shapes of the HGBL, NOS samples were larger than those of the BL samples. Since most specimens were obtained from medium-sized tumor cells with a diffuse hyperplasia and a partial large cell infiltration, small lymphocytes were rare ( Figure 1A and B). All cases showed similar morphological markers, which included the expression of mature B-cell markers (such as CD19, CD20, and CD22) that were detected by IHC. Table 1 (n=41). Overall, 13 (31.7%) patients had a MYC rearrangement only, 2 (4.9%) had a BCL2 rearrangement only, 3 (7.3%) had a BCL6 rearrangement only, and none of the patients had both BCL2 and BCL6 rearrangements. Three (7.3%) cases had both the copy number changes and gene rearrangements, which included 1 case with a MYC gene rearrangement and the copy number change of BCL2, 1 case with a BCL2 rearrangement and the MYC copy number change, and 1 case with both BCL2 copy number changes and rearrangements. Five (12.5%) cases had copy number changes without gene rearrangement, and the remaining cases had no cytogenetic abnormalities.
Clinical Features
The characteristics of 41 cases of HGBL, NOS patients have been listed in Table 2 . Twenty-six (63.4%) patients were male and 15 (36.6%) were female. The median follow-up duration was 28.0 months and from the beginning of the study to the end of the follow-up period, there were a total of 20 deaths. The median PFS was 6.0 months (95% CI: 0.035-11.965 months) and the median OS was 18.0 months (95% CI: 14.772-21.228 months) (Figure 2A and B) . Over a 2-year follow-up, the PFS rate was 41.5% and the OS rate was 36.7%.
All 41 patients received therapy which included R-CHOP regimen (n=17), DA-EPOCH-R regimen (n=8), R-CODOX-M/IVAC regimen (n=8), and R-Hyper-CVAD regimen (n=8). Fifteen (36.6%) patients, including 5 cases that received R-CHOP regimen, and 10 of other regimens, were treated with a CNS prophylaxis via an intrathecal injection. Six of the 41 (14.6%) patients received consolidation with an ASCT and 2 (4.9%) received a CAR-T therapy after disease relapse. The median number of chemotherapy cycles was 4 (range: 4 cycles-6 cycles). All 41 patients who were enrolled were evaluated for efficacy. Efficacy measures included CR (13 cases, 31.7%), PR (11 cases, 26.8%), SD (1 case, 2.4%), and PD (16 cases, 39.0%), and the ORR was 58.5%. The 41 patients were divided into 2 groups based on the therapeutic regimens (R-CHOP or high-intensity chemotherapy). Their baseline characteristics have been listed in Table 3 . Compared to patients treated with the R-CHOP regimen, those treated with a high-intensity chemotherapy (DA-EPOCH-R, R-Hyper-CVAD, or R-CODOX-M/IVAC) had superior PFS and OS (PFS: χ (Figure 3A and B) .
We performed subgroup analyses on DEL and non-DEL of HGBL, NOS. The PFS and OS of the patients who were non-DEL were superior to those of the DEL group (χ 2 =7.785, P=0.005 for PFS; χ 2 =4.563, P=0.033 for OS) ( Figure 4A and B) . The patients were then divided into 2 groups, based on whether they were diagnosed with SHL. Analyses showed a significant tendency toward better PFS and OS for patients who were non-SHL than those who were diagnosed with SHL (χ 2 =4.247, P=0.039 for Figure 6A and B). The other factors
were not independent prognostic factors ( Table 4) .
Discussion
HGBL, NOS belong to a heterogeneous category of rare, invasively mature B-cell lymphomas that are often difficult to classify during pathological diagnosis. 16, 17 In 2001, the WHO classified HGBL, NOS as the "atypical Burkitt's lymphoma" BL subtype. 18 In 2008, the WHO revised the classification of non-Hodgkin's lymphoma, which was classified separately as BCLU, DLBCL/BL. This new classification included lymphomas that were morphologically between BL and DLBCL but presented immunophenotypes that were close to those of the BL and the lymphomas that were morphologically similar to the BL, but were BCL2 positive and with or without MYC and BCL2 and/or BCL6 rearrangements. 19 MYC rearrangements as one separate hit have been found. 104 patients with DLBCL in a retrospective study and found that co-expression of MYC/BCL2 proteins was associated with a significantly inferior OS and an event-free survival (EFS) (P<0.05). In our study of HGBL, NOS, the results were similar to those of DLBCL. DEL has also been associated with an inferior survival, compared to that in the non-DEL. 28 DEL and SHL of HGBL, NOS had poor clinical outcomes in the general population of our study. Although the incidence of HGBL, NOS is low, accounting for 3% of the adult invasive B-cell lymphomas, and has a median age of onset of 55 (18-80) years. 7 Incidences are higher in males than in females. Patients with HGBL, NOS often present with an elevated LDH, bone marrow and CNS involvement, and a high IPI. In our study, the median age of onset was 41 (12 to 79) years, and the ratio of males to females was 1.7:1. Extranodal involvement occurred in 29 (70.7%) patients, which included 4 cases of a gastrointestinal tract invasion, 13 (34.1%) of the involvement of bone marrow, and 5 (12.2%) of involvement of the central nervous system. These findings are consistent with those reported in the literature. Perry et al 29 found that patients with BCLU with low IPI scores (0-2) and normal serum LDH levels had better survival rates. In agreement, our univariate analysis showed that for patients with HGBL, NOS, IPI score was an independent prognostic factor, while the other factors we investigated were not independent predictors of patient prognosis. Due to the limited knowledge and research on HGBL, NOS, there is no international consensus on a standard therapeutic approach for this lymphoma. 8 patients diagnosed with HGBL, R in a retrospective analysis, and showed that, compared to patients treated with other therapies, those treated with R-CODOX-M/IVAC had superior EFS12 (72% vs 39%, P=0.04), and although there was an improved OS (P=0.10), this was not significant. Taken together, these studies suggest that stronger chemotherapy regimens may improve the survival of patients with HGBL. In agreement, our study found that patients treated with intensive regimens (DA-EPOCH-R, R-CODOX-M/IVAC, or R-Hyper-CVAD) had superior PFS and OS. Of all the patients examined in this study, 6 received transplantation after chemotherapy, resulting in a complete remission in 5 patients, and a relapse half-a-year after transplant in one patient. Of the 2 patients who received CAR-T after the disease relapsed, 1 patient received regular followup and 1 patient died. Herrera et al 5 found that a relapsed or refractory DEL and DHL had inferior PFS after ASCT (P<0.05). For HGBL, NOS, intensive chemotherapy combined with ASCT seemed to improve the prognosis, but a larger sample size will be needed to verify this observation. CAR-T therapy is emerging as a novel treatment modality for lymphoma, 31 and further investigations on applicability of CAR-T therapy in HGBL, NOS will be needed.
Conclusion
In summary, our retrospective study showed that HGBL, NOS were highly malignant tumors that were associated with short survival. We suggest that a high-intensity chemotherapy combined with ASCT may prolong the survival of patients and that DEL and SHL appear to be associated with poor prognoses. Moreover, we suggest that an IPI score >2 may be a poor prognostic factor. However, due to the limitations inherent in our small sample size and retrospective analysis, we propose further prospective and largescale studies to clarify the clinical outcomes, effective treatments, and survival durations of patients with HGBL, NOS.
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